Tomahawk, WI 02/10/2014 (BasicsMedia) – Galena Biopharma Inc (NASDAQ:GALE) has started off 2014 on a sound footing. Thus far, it seems that everything GALE is doing is producing remarkable results. During the first three weeks of 2014, Galena saw a 40 percent increase in its stock. If you love healthcare stocks, this is one that you need to watch closely, as it appears to be on the verge of something great in 2014, probably unlike anything else it has achieved up to this point. The news coming out of Galena’s offices in the first two months of 2014 are positive and reassuring to investors across the board.

One reason behind the remarkable times that Galena Biopharma Inc (NASDAQ:GALE) has enjoyed thus far in 2014 is the fact that it has enrolled the first patient for the Phase 2 trial of its GALE-301. Under this trial, Galena hopes to come up with a product that will help to prevent the many cases of recurrent bouts of ovarian and endometrial cancer. GALE-301 is a folate binding protein and under this Phase 2 trial, Galena hopes that the first patient will use it together with an adjuvant and see a major reduction in the cases or instances of recurring endometrial and ovarian cancer.

The market has shown huge appreciation for this type of news from Galena Biopharma Inc (NASDAQ:GALE), and if this trend continues, healthcare investors who poured their money into this stock are set for a year of bumper harvest. Secondly, healthcare investors are pleased with what they are hearing and seeing from Galena, after the company announced that it intends to make an acquisition of Mills Pharmaceuticals, which comes up with solutions that are needed in the field of oncology. If this acquisition takes place as planned, it will herald the addition of GALE-401 into the mix.

GALE-401is meant for use in treating cases of essential thrombocythemia. If Galena Biopharma Inc (NASDAQ:GALE) goes ahead to make Mills Pharmaceuticals its latest acquisition, it stands to raise more than $200 million in revenue from the same of GALE-401 alone. This is the reason you will see many healthcare investors with investments in Galena smiling and being excited with what the company is doing. Although it may be impossible to ascertain how much progress the company has made by looking at the clinical trials, it is worth pointing out that the market is not worried.

Galena Biopharma Inc (NASDAQ:GALE) intends to develop a partnership with Dr. Reddy’s Laboratories, according to an announcement made on January 14, 2014. This deal would give Galena access and rights to Dr’ Reddy’s work regarding NeuVax in India. The project that Dr’ Reddy’s is undertaking in India is concerned with gaining more information regarding breast and gastric cancers in this massive country. Under this partnership, Galena is entitled to certain milestones related to development and sales, in addition to double-digit royalties for all net sales earned.

Galena Biopharma Inc (NASDAQ:GALE) is in safe hands, and enjoys strong leadership, which has thus far helped it in terms of attracting a larger number of healthcare investors. This appears to be in no danger based on the excitement that healthcare investors feel towards Galena. If you have been looking for healthcare investment, you should not allow Galena to pass right through your grip.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.